...
首页> 外文期刊>Journal of Hand Surgery. American Volume >Upper extremity spasticity in children with cerebral palsy: A randomized, double-blind, placebo-controlled study of the short-term outcomes of treatment with botulinum a toxin
【24h】

Upper extremity spasticity in children with cerebral palsy: A randomized, double-blind, placebo-controlled study of the short-term outcomes of treatment with botulinum a toxin

机译:脑性瘫痪患儿的上肢痉挛:肉毒杆菌毒素治疗短期结果的随机,双盲,安慰剂对照研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose: Botulinum A toxin (BoNT-A) injections are used widely to manage lower extremity spasticity in children with cerebral palsy. However, their use in the upper extremity is less well defined. This randomized, double-blind, placebo-controlled clinical trial evaluated the safety and efficacy of upper extremity intramuscular injections of BoNT-A in a cross-section of children with varying levels of function. Methods: Upper extremity function of study participants (N = 73; M:F = 47:26; age range, 3-18 y) was evaluated using the House Classification system (scores, 0-8, where a higher score indicates higher functional ability). Three groups of children were identified based on their House scores: 0-2 (n = 10), 3-5 (n = 54), and 6-8 (n = 9). Following randomization, children received a BoNT-A or placebo injection at baseline. Injections were administered at 8 and 20 weeks if clinically indicated. Occupational therapists evaluated study participants at screening, at baseline, and at 4, 8, 14, 20, and 26 weeks. Physician evaluations occurred at baseline and at 8, 20, and 26 weeks. The Melbourne Assessment of Unilateral Upper Limb Function evaluated the quality of upper extremity function before and after injections and served as the primary outcome variable. Results: The majority of study participants underwent 3 injection sessions. Muscles injected were individualized based on each child's particular spasticity pattern. A statistically higher percentage of children receiving BoNT-A injections showed an improvement in the Melbourne assessment at 26 weeks compared with the children receiving placebo. The range, frequency, and severity of postinjection adverse events were similar in both groups. Conclusions: Children receiving BoNT-A injections demonstrated clinically meaningful short-term improvements in upper extremity function. Injections were well tolerated and safe. In contrast to other studies, study participants underwent multiple injection sessions based on their individual spasticity patterns. Type of study/level of evidence: Therapeutic I. ? 2013 American Society for Surgery of the Hand.
机译:目的:肉毒杆菌毒素(BoNT-A)注射液被广泛用于控制脑瘫患儿的下肢痉挛。但是,它们在上肢的用途尚不明确。这项随机,双盲,安慰剂对照的临床试验评估了BoNT-A上肢肌肉注射剂在功能水平不同的儿童横断面中的安全性和有效性。方法:使用房屋分类系统(得分0-8)评估研究参与者的上肢功能(N = 73; M:F = 47:26;年龄范围:3-18岁),其中得分越高表示功能越高能力)。根据他们的众议院分数确定了三组儿童:0-2(n = 10),3-5(n = 54)和6-8(n = 9)。随机分组后,儿童在基线时接受BoNT-A或安慰剂注射。如果有临床指征,则在第8和20周注射。职业治疗师在筛选,基线以及第4、8、14、20和26周时对研究参与者进行了评估。在基线以及第8、20和26周进行医师评估。墨尔本单侧上肢功能评估评估了注射前后上肢功能的质量,并作为主要结果变量。结果:大多数研究参与者进行了3次注射。注射的肌肉根据每个孩子的特定痉挛模式进行个性化设置。与接受安慰剂的儿童相比,接受BoNT-A注射的儿童在26周时的统计数字更高,表明墨尔本评估的结果有所改善。两组注射后不良事件的范围,频率和严重程度相似。结论:接受BoNT-A注射的儿童在上肢功能方面显示出临床上有意义的短期改善。注射剂耐受良好且安全。与其他研究相反,研究参与者根据各自的痉挛模式进行了多次注射。研究类型/证据级别:治疗I。 2013年美国手外科学会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号